Panacea Biotec Reports Q3 FY26 Standalone/Consolidated Unaudited Results
Panacea Biotec reported Q3 FY26 unaudited results. Standalone net loss after tax was ₹736 lakh (vs ₹965 lakh profit YoY). Consolidated net profit after tax was ₹389 lakh for the quarter. Nine-month standalone net loss was ₹2,970 lakh, and consolidated net profit was ₹389 lakh. The company is operating on a going concern basis.
The financial results show a net loss on a standalone basis and a significant change in profitability compared to the previous year, which can impact investor sentiment and the company's valuation. However, the ongoing business orders and efforts to improve performance provide some positive outlook.
The company reported a net loss for the quarter and nine months ended December 31, 2025, on a standalone basis, and while consolidated results showed a profit for the quarter, the overall financial performance indicates a negative trend compared to the previous year's results.
Panacea Biotec Limited announced its standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on February 11, 2026, following a review by the Audit Committee and the Statutory Auditors.
The company reported a total income from operations of ₹9,931 lakh for the standalone quarter ended December 31, 2025, compared to ₹10,843 lakh in the same quarter of the previous year. The net loss after tax for the standalone quarter was ₹736 lakh, a change from a profit of ₹965 lakh in the prior year's quarter. For the nine months ended December 31, 2025, the standalone total income was ₹30,237 lakh, with a net loss after tax of ₹2,970 lakh.
On a consolidated basis, the total income from operations for the quarter ended December 31, 2025, was ₹16,519 lakh, and the net profit after tax was ₹389 lakh. For the nine months ended December 31, 2025, the consolidated total income stood at ₹47,302 lakh, with a net profit after tax of ₹389 lakh. The management has prepared the financial results on a going concern basis, citing higher long-term business orders for vaccines and continuous efforts to improve business performance.
An exceptional income of ₹1,679 lakh was recognized in the consolidated statement for the nine months ended December 31, 2025, which includes revenue from a settlement agreement with Apotex, USA, and recognition of deferred consideration from the sale of pharmaceutical brands.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.